Despite advances in cancer genetics and treatment, anticancer drug resistance remains a formidableproblem and challenge to oncologists and researchers alike. The long-term goat of this project has been the dissection of mechanisms of tumor multidrug resistance. It was known previously that anticancer drug resistance at the cellular level, even to a single agent, is a multifactorial phenomenon;multiple genetic changes can occur in a tumor cell selected for resistance to any particular cytotoxic agent. Complementing this view, we have learned more recently that the putative targets of anticancer agents and mediators of their actions play complex roles in cellular physiology and drug responsiveness. For example, topoisomerases undergo post- translational modifications in response to drug treatments, and these modifications have revealed a complex signaling pathway involving sumoylation that is also involved in drug responses. Further, with regard to ABC transporters, which mediate multidrug resistance, we have learned that one member of this class, MRP1/ABCC1, appears to be regulated by the signaling molecule Notch-1, and that another member, BCRP/ABCG2, is regulated by estrogen. Accordingly, study of novel mechanisms of regulation of ABC protein expression may afford unique methods to circumvent drug resistance. Thus, expanding on the historical focus of our laboratory efforts in ABC transporters and topoisomerases, we wish to build on the new knowledge of the past few years and on the progress we have made in the prior funding period to test the hypothesis that novel regulatory mechanisms for expression of topoisomerases and ABC proteins affect anticancer drug responses and offer insights into new therapeutic paradigms. Building on work done in the prior funding period, I offer here a focused application and propose the following specific aims to test our hypothesis: (1) Define the molecular mechanisms of regulation of topoisomerases in mammalian tumors and drug-mediated cytotoxiciry through these enzymes;(2) Define the role of Ubc9 and protein sumoylation in anticancer drug responsiveness;and (3) Define the molecular mechanisms of novel regulation by Notch-1 of expression of the ABC transporter,MRP1/ABCC1.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-ONC-Q (01))
Program Officer
Forry, Suzanne L
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Illinois at Chicago
Schools of Pharmacy
United States
Zip Code
Ho, Tsui-Ting; He, Xiaolong; Mo, Yin-Yuan et al. (2016) Transient resistance to DNA damaging agents is associated with expression of microRNAs-135b and -196b in human leukemia cell lines. Int J Biochem Mol Biol 7:27-47
Xie, Yi; Natarajan, Karthika; Bauer, Kenneth S et al. (2013) Bcrp1 transcription in mouse testis is controlled by a promoter upstream of a novel first exon (E1U) regulated by steroidogenic factor-1. Biochim Biophys Acta 1829:1288-99
Chen, Cheng-Fen; He, Xiaolong; Arslan, Ahmet Dirim et al. (2011) Novel regulation of nuclear factor-YB by miR-485-3p affects the expression of DNA topoisomerase II? and drug responsiveness. Mol Pharmacol 79:735-41
He, X; Arslan, A D; Pool, M D et al. (2011) Knockdown of splicing factor SRp20 causes apoptosis in ovarian cancer cells and its expression is associated with malignancy of epithelial ovarian cancer. Oncogene 30:356-65
Cho, Sungpil; Lu, Meiling; He, Xiaolong et al. (2011) Notch1 regulates the expression of the multidrug resistance gene ABCC1/MRP1 in cultured cancer cells. Proc Natl Acad Sci U S A 108:20778-83
Natarajan, Karthika; Xie, Yi; Nakanishi, Takeo et al. (2011) Identification and characterization of the major alternative promoter regulating Bcrp1/Abcg2 expression in the mouse intestine. Biochim Biophys Acta 1809:295-305
Das, Sonia G; Srinivasan, Balasubramanian; Hermanson, David L et al. (2011) Structure-activity relationship and molecular mechanisms of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and its analogues. J Med Chem 54:5937-48
Wu, Fangting; Zhu, Shuomin; Ding, Yanna et al. (2009) MicroRNA-mediated regulation of Ubc9 expression in cancer cells. Clin Cancer Res 15:1550-7
Wu, Fangting; Chiocca, Susanna; Beck, William T et al. (2007) Gam1-associated alterations of drug responsiveness through activation of apoptosis. Mol Cancer Ther 6:1823-30
Mo, Yin-Yuan; Yu, Yanni; Theodosiou, Elena et al. (2005) A role for Ubc9 in tumorigenesis. Oncogene 24:2677-83

Showing the most recent 10 out of 78 publications